Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Vandetanib (ZD6474; ZACTIMA, AstraZeneca) is a once-daily, orally available agent with potential for use in a number of solid tumor types. Vandetanib targets key signaling pathways in cancer by inhibiting VEGFR-dependent tumor angiogenesis, and EGFR- and RET-dependent tumor cell proliferation and survival. Phase I studies showed vandetanib to be generally well tolerated at doses of < or = 300 mg/day, with a pharmacokinetic profile that supports once-daily oral administration. Phase II evaluation of vandetanib in patients with advanced refractory NSCLC has demonstrated improvements in progression-free survival both as monotherapy (versus gefitinib) and in combination with docetaxel (versus docetaxel alone). These positive outcomes have led to the initiation of Phase III trials of vandetanib in advanced NSCLC. Clinical development is also ongoing in other tumor types and encouraging evidence of antitumor activity has been reported in patients with metastatic hereditary medullary thyroid cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“VEGF has been identified as the most potent and specific mitogen for vascular endothelial cells and it is now widely accepted that VEGF/VEGFR signaling is a key driver of tumor angiogenesis [1].”
BackgroundPaclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · cited 2×
“Drugs (2007) 16(2) or NSCLC [3], and in progression-free survival for patients with breast cancer [4].”
BackgroundErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“Gefitinib and erlotinib are small-molecule inhibitors of the EGFR tyrosine kinase and both have demonstrated clinical benefit as monotherapy in patients with NSCLC after failure of first-line chemotherapy [6-9].”
BackgroundCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 1×
“Furthermore, the monoclonal anti-EGFR antibody cetuximab showed clinically significant activity when used alone or in combination with chemotherapy in metastatic colorectal cancer [10].”
BackgroundKris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Self-citationThatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079 · cited 1×
“Gefitinib and erlotinib are small-molecule inhibitors of the EGFR tyrosine kinase and both have demonstrated clinical benefit as monotherapy in patients with NSCLC after failure of first-line chemotherapy [6-9].”
BackgroundHerbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490 · cited 1×
“In this context, it is worth noting that the VEGF inhibitor bevacizumab (but not the EGFR inhibitors gefitinib or erlotinib) prolonged survival in previously untreated patients with NSCLC when added to a standard carboplatin and paclitaxel regimen [3,50,51] (the bevacizumab trial enrolled only non-squamous patients).”
BackgroundEpidermal growth factor receptor inhibition strategies in oncology
Harari, P. M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00600 · Cited by 423
Cited by
Herbst, R. S., Sun, Y., Eberhardt, W. E., Germonpré, P., Saijo, N., Zhou, C., Wang, J., Li, L., Kabbinavar, F., Ichinose, Y., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70132-7 · Cited by 415
Self-citationThyroid carcinoma: molecular pathways and therapeutic targets
Nikiforov, Y. E. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.10 · Cited by 392
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
Le, X., Nilsson, M., Goldman, J., Reck, M., Nakagawa, K., Kato, T., Ares, L. P., Frimodt-Moller, B., Wolff, K., Visseren-Grul, C., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.006 · Cited by 339
Self-citationEGFR family: Structure physiology signalling and therapeutic targets †
Burgess, A. W. (2008) · Growth Factors · doi:10.1080/08977190802312844 · Cited by 288
Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis
Nikiforova, M. N., & Nikiforov, Y. E. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.1.83 · Cited by 277
Metadata
- Authors
- Herbst, R. S., Heymach, J. V., O’Reilly, M. S., Onn, A., & Ryan, A. J.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2007-01-24
- Volume
- 16
- Issue
- 2
- Pages
- 239-249
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2147289344
- Cited by
- 143
- References
- 8
- FWCI
- 19.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.